Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21210764 | 0.94 | HTT (0.58) | HDAC3NAAALMNASMN1; SMN2TSHR | |
| SCHEMBL13753140 | 0.88 | L3MBTL1 (0.54) | HDAC3ALDH1A1L3MBTL1HPGDNPC1 | |
| SCHEMBL9317521 | 0.85 | ACKR3 (0.53) | HDAC3NAAACNR1CNR2 | |
| SCHEMBL31320036 | 0.83 | NAAA (0.51) | HDAC3NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL27379972 | 0.82 | NAAA (0.50) | NAAAALDH1A1LMNASMN1; SMN2CNR1 | |
| SCHEMBL28929321 | 0.82 | NAAA (0.70) | HDAC3NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6068233 | 0.81 | CES2 (0.55) | HDAC3LMNASMN1; SMN2L3MBTL1TP53 | |
| SCHEMBL12121122 | 0.81 | HTT (0.57) | HDAC3NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5636971 | 0.80 | ALPL (0.55) | HDAC3ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL12462063 | 0.80 | HDAC3 (0.54) | HDAC3LMNATSHRL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | HDAC3 266/4885NAAA 4148/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.